Knockdown of ubiquitin associated protein 2-like inhibits the growth and migration of prostate cancer cells

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1578-1584

  Li, Dong ^a   Huang, Yiran ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Migration; Proliferation; Prostate cancer; RNA interference; UBAP2L

Indexed keywords

BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; LENTIVIRUS VECTOR; MESSENGER RNA; PROTEIN BAD; PROTEIN SERINE THREONINE KINASE; SHORT HAIRPIN RNA; UBIQUITIN ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG; AKT1S1 PROTEIN, HUMAN; BAD PROTEIN, HUMAN; CARRIER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UBAP2L PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE CARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CARCINOMA; CELL CYCLE CHECKPOINT; CELL MOTION; DRUG SCREENING; GENETICS; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMP-ACTIVATED PROTEIN KINASES; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA; CARRIER PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY;

EID: 84918836270     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3360     Document Type: Article

References (18)

1. Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53: 171-184, 2009.
2. McGarrity GJ, Hoyah G, Winemiller A, et al: Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med 15: 78-82, 2013.
3. Chen FZ and Zhao XK: Ubiquitin-proteasome pathway and prostate cancer. Onkologie 36: 592-596, 2013.
4. Iqbal M, Messina McLaughlin PA, Dunn D, et al: Proteasome inhibitors for cancer therapy. Bioorg Med Chem 20: 2362-2368, 2012.
5. Crawford LJ, Walker B and Irvine AE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5: 101-110, 2011.
6. Rastogi N and Mishra DP: Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div 7: 26, 2012.
7. San-Miguel JF, Richardson PG, Gunther A, et al : Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31: 3696-3703, 2013.
8. O'Brien ME, Gaafar RM, Popat S, et al: Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 49: 2815-2822, 2013.
9. Wilde IB, Brack M, Winget JM and Mayor T: Proteomic characterization of aggregating proteins after the inhibition of the ubiquitin proteasome system. J Proteome Res 10: 1062-1072, 2011.
10. Chuang HC, Chou CC, Kulp SK and Chen CS: AMPK as a potential anticancer target - friend or foe? Curr Pharm Des 20: 2607-2618, 2013.
11. Kazi AA and Lang CH: PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts. Mol Med 16: 359-371, 2010.
12. Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M and Kulik G: Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One 4: e6224, 2009.
13. Li J, Coven DL, Miller EJ, et al: Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol 291: H1927-H1934, 2006. (Pubitemid 44497701)
14. Sastry KS, Smith AJ, Karpova Y, Datta SR and Kulik G: Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J Biol Chem 281: 20891-20901, 2006. (Pubitemid 44115430)
15. Datta SR, Katsov A, Hu L, et al: 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6: 41-51, 2000.
16. Fang X, Yu S, Eder A, et al: Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18: 6635-6640, 1999.
17. Tan Y, Demeter MR, Ruan H and Comb MJ: BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 275: 25865-25869, 2000.
18. Sancak Y, Thoreen CC, Peterson TR, et al: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915, 2007. (Pubitemid 46436534)